Reduced vesicular storage of catecholamines causes progressive degeneration in the locus ceruleus

Neuropharmacology

Volumn 76, Issue PART A, 2014, Pages 97-105

  Taylor, Tonya N ^a,b   Alter, Shawn P ^a,b   Wang, Minzheng ^a,b   Goldstein, David S ^c   Miller, Gary W ^a,b  

^a Center for Neurodegenerative Disease   (United States)

^b EMORY UNIVERSITY   (United States)

^c NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE   (United States)

Author keywords

Locus ceruleus; Norepinephrine; Parkinson's disease; VMAT2

Indexed keywords

DOPAMINE; NISOXETINE; NORADRENALIN; VESICULAR MONOAMINE TRANSPORTER;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BRAIN; CATECHOLAMINERGIC SYSTEM; CONTROLLED STUDY; DISEASE COURSE; DISEASE PREDISPOSITION; ENZYME ACTIVITY; FEMALE; HEART; IMMUNOREACTIVITY; IN VIVO STUDY; LOCUS CERULEUS; MALE; MOUSE; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN BINDING; PROTEIN BLOOD LEVEL; PROTEIN DEGRADATION; PROTEIN DEPLETION; PROTEIN EXPRESSION; PROTEIN HOMEOSTASIS; PROTEIN LOCALIZATION; SUBSTANTIA NIGRA PARS COMPACTA; VENTRAL TEGMENTUM;

3,4-DIHYDROXYPHENYLACETALDEHYDE; 3,4-DIHYDROXYPHENYLACETIC ACID; 3,4-DIHYDROXYPHENYLGLYCOL; 3-4-DIHYDROXYPHENYLGLYCOLALDEHYDE; DA; DHPG; DOPAC; DOPAL; DOPAMINE; DOPEGAL; LC; LOCUS CERULEUS; MAO; MONOAMINE OXIDASE; NE; NET; NOREPINEPHRINE; NOREPINEPHRINE TRANSPORTER; PARKINSON'S DISEASE; SNPC; SUBSTANTIA NIGRA PARS COMPACTA; TH; TYROSINE HYDROXYLASE; VENTRAL TEGMENTAL AREA; VESICULAR MONOAMINE TRANSPORTER 2; VMAT2; VTA;

ANIMALS; CATECHOLAMINES; CEREBRAL CORTEX; CORPUS STRIATUM; DOPAMINE; FEMALE; LOCUS COERULEUS; MALE; MICE; MICE, NEUROLOGIC MUTANTS; MYOCARDIUM; NERVE DEGENERATION; NOREPINEPHRINE; NOREPINEPHRINE PLASMA MEMBRANE TRANSPORT PROTEINS; PARKINSON DISEASE; VESICULAR MONOAMINE TRANSPORT PROTEINS;

EID: 84886587153     PISSN: 00283908     EISSN: 18737064     Source Type: Journal    
DOI: 10.1016/j.neuropharm.2013.08.033     Document Type: Article

References (61)

1. T. Amino Profound cardiac sympathetic denervation occurs in Parkinson disease Brain Pathol. 15 2005 29 34 (Pubitemid 40224064)
2. S.M. Antelman, and A.R. Caggiula Norepinephrine-dopamine interactions and behavior Science 195 1977 646 653
3. H. Braak Staging of the intracerebral inclusion body pathology associated with idiopathic Parkinson's disease (preclinical and clinical stages) J. Neurol. 249 Suppl. 3 2002 III/1-5
4. H. Braak Staging of brain pathology related to sporadic Parkinson's disease Neurobiol. Aging 24 2003 197 211 (Pubitemid 36007810)
5. L. Brighina Analysis of vesicular monoamine transporter 2 polymorphisms in Parkinson's disease Neurobiol. Aging 34 6 2013 1712.e9 1712.e13
6. W.J. Burke Aggregation of alpha-synuclein by DOPAL, the monoamine oxidase metabolite of dopamine Acta Neuropathol. 115 2008 193 203
7. W.J. Burke Neurotoxicity of MAO metabolites of catecholamine neurotransmitters: role in neurodegenerative diseases NeuroToxicology 25 2004 101 115 (Pubitemid 38044173)
8. W.M. Caudle Altered vesicular dopamine storage in Parkinson's disease: a premature demise Trends Neurosci. 31 2008 303 308
9. W.M. Caudle Polychlorinated biphenyl-induced reduction of dopamine transporter expression as a precursor to Parkinson's disease-associated dopamine toxicity Toxicol. Sci. 92 2006 490 499 (Pubitemid 44018965)
10. W.M. Caudle Reduced vesicular storage of dopamine causes progressive nigrostriatal neurodegeneration J. Neurosci. 27 2007 8138 8148 (Pubitemid 47173329)
11. V. Chan-Palay, and E. Asan Quantitation of catecholamine neurons in the locus coeruleus in human brains of normal young and older adults and in depression J. Comp. Neurol. 287 1989 357 372 (Pubitemid 19239068)
12. R.E. Colebrooke Age-related decline in striatal dopamine content and motor performance occurs in the absence of nigral cell loss in a genetic mouse model of Parkinson's disease Eur. J. Neurosci. 24 2006 2622 2630 (Pubitemid 44726774)
13. K.A. Conway Kinetic stabilization of the alpha-synuclein protofibril by a dopamine-alpha-synuclein adduct Science 294 2001 1346
14. F.M. Corrigan Diorthosubstituted polychlorinated biphenyls in caudate nucleus in Parkinson's disease Exp. Neurol. 150 1998 339 342 (Pubitemid 28231967)
15. I. Cruz-Muros Deglycosylation and subcellular redistribution of VMAT2 in the mesostriatal system during normal aging Neurobiol. Aging 29 2008 1702 1711
16. J. Cubells Methamphetamine neurotoxicity involves vacuolation of endocytic organelles and dopamine-dependent intracellular oxidative stress J. Neurosci. 14 1994 2260 2271 (Pubitemid 24108131)
17. M. Dae Imaging of myocardial sympathetic innervation with metaiodobenzylguanidine J. Nucl. Cardiol. 1 1994 S23 S30
18. W. Dauer, and S. Przedborski Parkinson's disease: mechanisms and models Neuron 39 2003 889 909 (Pubitemid 37130207)
19. K. Del Tredici, and H. Braak Dysfunction of the locus coeruleus-norepinephrine system and related circuitry in Parkinson's disease-related dementia J. Neurol. Neurosurg. Psychiatr. 84 7 2012 774 783
20. L.S. Forno Neuropathology of Parkinson's disease J. Neuropathol. Exp. Neurol. 55 1996 259 272 (Pubitemid 26085575)
21. D.C. German Midbrain dopaminergic cell loss in Parkinson's disease and MPTP-induced parkinsonism: sparing of calbindin-D25k - containing cells Ann. N. Y. Acad. Sci. 648 1992 42 62
22. M. Gesi The role of the locus coeruleus in the development of Parkinson's disease Neurosci. Biobehav. Rev. 24 2000 655 668 (Pubitemid 30625131)
23. C.E. Glatt Gain-of-function haplotypes in the vesicular monoamine transporter promoter are protective for Parkinson disease in women Hum. Mol. Genet. 15 2006 299 305 (Pubitemid 43125983)
24. D.S. Goldstein Dysautonomia in Parkinson's disease: neurocardiological abnormalities Lancet Neurol. 2 2003 669 676 (Pubitemid 37311320)
25. D.S. Goldstein Intra-neuronal vesicular uptake of catecholamines is decreased in patients with Lewy body diseases J. Clin. Invest. 121 2011 3320 3330
26. D.S. Goldstein Cardiac sympathetic denervation preceding motor signs in Parkinson disease Clin. Auton. Res. 17 2007 118 121 (Pubitemid 46669418)
27. D.S. Goldstein Catechols in post-mortem brain of patients with Parkinson disease Eur. J. Neurol. 18 2011 703 710
28. D.S. Goldstein Determinants of buildup of the toxic dopamine metabolite DOPAL in Parkinson disease J. Neurochem. 126 5 2013 591 603
29. T.S. Guillot Reduced vesicular storage of dopamine exacerbates methamphetamine-induced neurodegeneration and astrogliosis J. Neurochem. 106 2008 2205 2217
30. G.M. Halliday Loss of brainstem serotonin- and substance P-containing neurons in Parkinson's disease Brain Res. 510 1990 104 107 (Pubitemid 20060808)
31. J.M. Hatcher-Martin Association between polychlorinated biphenyls and Parkinson's disease neuropathology NeuroToxicology 33 2012 1298 1304
32. C. Holmes Improved assay for plasma dihydroxyphenylacetic acid and other catechols using high-performance liquid chromatography with electrochemical detection J. Chromatogr. B Biomed. Sci. Appl. 653 1994 131 138 (Pubitemid 24085051)
33. D.M. Mann The locus coeruleus and its possible role in ageing and degenerative disease of the human central nervous system Mech. Ageing Dev. 23 1983 73 94 (Pubitemid 14240536)
34. A.L. McCormack Environmental risk factors and Parkinson's disease: selective degeneration of nigral dopaminergic neurons caused by the herbicide paraquat Neurobiol. Dis. 10 2002 119 127 (Pubitemid 34775465)
35. G.W. Miller Immunochemical analysis of vesicular monoamine transporter (VMAT2) protein in Parkinson's disease Exp. Neurol. 156 1999 138 148 (Pubitemid 29152991)
36. G.W. Miller Immunochemical analysis of dopamine transporter protein in Parkinson's disease Ann. Neurol. 41 1997 530 539 (Pubitemid 27169193)
37. K.A. Mooslehner Mice with very low expression of the vesicular monoamine transporter 2 gene survive into adulthood: potential mouse model for parkinsonism Mol. Cell Biol. 21 2001 5321 5331 (Pubitemid 32702438)
38. E.V. Mosharov Interplay between cytosolic dopamine, calcium, and α-synuclein causes selective death of substantia nigra neurons Neuron 62 2009 218 229
39. T. Murai In vivo evidence for differential association of striatal dopamine and midbrain serotonin systems with neuropsychiatric symptoms in Parkinson's disease J. Neuropsychiatry Clin. Neurosci. 13 2001 222 228 (Pubitemid 32499674)
40. W. Paulus, and K. Jellinger The neuropathologic basis of different clinical subgroups of Parkinsons-disease J. Neuropathol. Exp. Neurol. 50 1991 743 755.
41. G. Paxinos, and K.B.J. Franklin The Mouse Brain in Stereotaxic Coordinates second ed. 2001 Academic Press San Diego
42. M.E. Reveron L-DOPA does not cause neurotoxicity in VMAT2 heterozygote knockout mice Neurotoxicology 23 2002 611 619 (Pubitemid 36527681)
43. K.S. Rommelfanger, and D. Weinshenker Norepinephrine: the redheaded stepchild of Parkinson's disease Biochem. Pharmacol. 74 2007 177 190 (Pubitemid 46890808)
44. A.H. Schapira Mitochondrial pathology in Parkinson's disease Mt. Sinai J. Med. 78 2011 872 881
45. C.C. Smith, and R.W. Greene CNS dopamine transmission mediated by noradrenergic innervation J. Neurosci. 32 2012 6072 6080
46. C.G. Specht, and R. Schoepfer Deletion of the alpha-synuclein locus in a subpopulation of C57BL/6J inbred mice BMC Neurosci. 2 2001 11
47. D. Sulzer [alpha]-synuclein and cytosolic dopamine: stabilizing a bad situation Nat. Med. 7 2001 1280 1282 (Pubitemid 34007922)
48. D. Sulzer, and D.J. Surmeier Neuronal vulnerability, pathogenesis, and Parkinson's disease Move. Disord. 28 6 2012 715 724
49. D. Sulzer, and L. Zecca Intraneuronal dopamine-quinone synthesis: a review Neurotoxicity Res. 1 1999 181 195
50. D.J. Surmeier A lethal convergence of dopamine and calcium Neuron 62 2009 163 164
51. D.J. Surmeier Autonomous pacemakers in the basal ganglia: who needs excitatory synapses anyway? Curr. Opin. Neurobiol. 15 2005 312 318 (Pubitemid 40806443)
52. N. Takahashi VMAT2 knockout mice: heterozygotes display reduced amphetamine-conditioned reward, enhanced amphetamine locomotion, and enhanced MPTP toxicity Proc. Natl. Acad. Sci. 94 1997 9938 9943
53. T.N. Taylor VMAT2-deficient mice display nigral and extranigral pathology and motor and nonmotor symptoms of Parkinson's disease Parkinsons Dis. 2011 2011 124165
54. T.N. Taylor Nonmotor symptoms of Parkinson's disease revealed in an animal model with reduced monoamine storage capacity J. Neurosci. 29 2009 8103 8113
55. S.M. Tejani-Butt [3H]nisoxetine: a radioligand for quantitation of norepinephrine uptake sites by autoradiography or by homogenate binding J. Pharmacol. Exp. Ther. 260 1992 427 436
56. G.R. Uhl The VMAT2 gene in mice and humans: amphetamine responses, locomotion, cardiac arrhythmias, aging, and vulnerability to dopaminergic toxins FASEB J. 14 2000 2459 2465
57. A. Ulusoy Dysregulated dopamine storage increases the vulnerability to α-synuclein in nigral neurons Neurobiol. Dis. 47 2012 367 377
58. D.C. Velseboer Prevalence of orthostatic hypotension in Parkinson's disease: a systematic review and meta-analysis Parkinsonism Relat. Disord. 17 2011 724 729
59. Y.M. Wang Knockout of the vesicular monoamine transporter 2 gene results in neonatal death and supersensitivity to cocaine and amphetamine Neuron 19 1997 1285 1296
60. M.J. West Unbiased stereological estimation of the total number of neurons in thesubdivisions of the rat hippocampus using the optical fractionator Anat. Rec. 231 1991 482 497
61. C. Zarow Neuronal loss is greater in the locus coeruleus than nucleus basalis and substantia nigra in Alzheimer and Parkinson diseases Arch. Neurol. 60 2003 337 341 (Pubitemid 36314358)